BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Call Transcript
Operator: Good day, and welcome to the BioCryst First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode.
Biocryst Pharmaceuticals Inc (BCRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 3,052,137 | $22,891,027 | -5% | 0.01% |
| 2. | Renaissance Technologies Jim Simons | 605,218 | $4,539,135 | +12% | 0.01% |
| 3. | Hudson Bay Capital Management Sander Gerber | 498,679 | $3,740,093 | 0.01% | |
| 4. | Dorset Management David M. Knott | 460,000 | $3,450,000 | +5% | 1.63% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 194,152 | $1,456,140 | -52% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.36 | 7,861 | Director | 44,951 | 2024-05-30 | Filing | |
| $6.40 | 2,500 | Director | 2,500 | 2024-05-24 | Filing | |
| $6.38 | 5,000 | Director | 86,818 | 2024-05-20 | Filing | |
| $6.25 | 15,000 | Director | 66,997 | 2024-05-20 | Filing | |
| $5.57 | 36,300 | Officer | 266,744 | 2024-05-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.54 | 7,000 | Director | 86,638 | 2024-12-13 | Filing | |
| $6.32 | 8,600 | Director | 27,831 | 2024-06-24 | Filing | |
| $6.00 | 4,689 | Director | 27,742 | 2024-06-17 | Filing | |
| $6.11 | 6,698 | Director | 52,852 | 2024-06-14 | Filing | |
| $7.98 | 4,000 | Director | 25,611 | 2023-06-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,769,246 | $170,769,349 | 0% | |
| 2. | 21,659,765 | $162,448,239 | 0% | |
| 3. | 4,960,637 | $37,213,423 | 0% | |
| 4. | 3,846,154 | $28,846,155 | 20.78% | |
| 5. | 2,403,186 | $18,023,896 | 0% |
News See All
10 Best Small-Cap Stocks to Buy Now
The S&P 500 index has reached its all-time highs, achieving returns of over 20% for two second consecutive years post-COVID.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript February 24, 2025BioCryst Pharmaceuticals, Inc. misses on earnings expectations.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript
Operator: Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.
Piper Sandler's Top Technical Stock Picks: 20 Best Stocks
The start of October has seen another wild swing for markets. September's second half saw Wall Street rejoice as the Federal Reserve delivered its highly anticipated interest rate cut.
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call Transcript August 5, 2024BioCryst Pharmaceuticals, Inc. beats earnings expectations.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23.
12 Best Depressed Stocks To Buy in 2024
JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite low when compared to market expectations.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
Billionaire Hedge Funds
